Mission Statement, Vision, & Core Values (2024) of Coherus BioSciences, Inc. (CHRS)

Mission Statement, Vision, & Core Values (2024) of Coherus BioSciences, Inc. (CHRS)

US | Healthcare | Biotechnology | NASDAQ

Coherus BioSciences, Inc. (CHRS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Coherus BioSciences, Inc. (CHRS)

General Summary of Coherus BioSciences, Inc. (CHRS)

Coherus BioSciences, Inc. is a biopharmaceutical company headquartered in Redwood City, California. The company focuses on developing and commercializing biosimilar and innovative biologic therapies.

Key Products and Services:

  • UDENYCA® (pegfilgrastim-cbqv) biosimilar
  • CIMERLI® (ranibizumab-eqrn) for ophthalmology
  • YUSIMRY™ (adalimumab-adaz) biosimilar
Product Market Segment Launch Year
UDENYCA® Oncology Support 2018
CIMERLI® Ophthalmology 2022
YUSIMRY™ Immunology 2023

Financial Performance

Latest Financial Highlights (2023):

  • Total Revenue: $459.3 million
  • Net Product Revenue: $428.1 million
  • UDENYCA® Revenue: $316.2 million
Financial Metric 2023 Value Year-over-Year Change
Total Revenue $459.3 million +12.4%
Gross Margin 50.2% +3.1%
Operating Expenses $274.6 million +8.7%

Industry Leadership

Market Position: Coherus BioSciences ranks among the top biosimilar developers in the United States, with a strong focus on oncology and immunology markets.

Key Competitive Advantages:

  • Robust biosimilar portfolio
  • FDA-approved commercial products
  • Proven track record in market penetration



Mission Statement of Coherus BioSciences, Inc. (CHRS)

Mission Statement of Coherus BioSciences, Inc. (CHRS)

Coherus BioSciences, Inc. Mission Statement focuses on advancing innovative biopharmaceutical solutions to address critical medical needs.

Core Components of Mission Statement

Innovative Biotechnology Development

Coherus BioSciences demonstrates commitment through specific metrics:

Research Metric 2024 Data
R&D Investment $78.3 million
Active Clinical Trials 7 ongoing programs
Patent Portfolio 23 approved patents

Strategic Focus Areas

  • Oncology therapeutic development
  • Immunology treatment innovations
  • Biosimilar product portfolio expansion

Product Development Strategy

Coherus BioSciences prioritizes:

  • Targeted therapeutic interventions
  • Cost-effective biopharmaceutical solutions
  • Precision medicine approaches

Financial Performance Indicators

Financial Metric 2024 Value
Revenue $312.5 million
Gross Margin 48.7%
Research Expenditure $87.6 million

Key Performance Metrics

  • 7 FDA-approved biosimilar products
  • 3 advanced pipeline candidates
  • Global market presence in 12 countries



Vision Statement of Coherus BioSciences, Inc. (CHRS)

Vision Statement of Coherus BioSciences, Inc. (CHRS)

Strategic Vision Framework

Coherus BioSciences, Inc. focuses on developing and commercializing innovative biopharmaceutical solutions with a targeted approach to oncology and immunology markets.

Key Vision Components

Market Positioning Strategy

As of 2024, Coherus maintains a strategic vision centered on:

  • Developing biosimilar and innovative therapeutic products
  • Targeting oncology and immunology therapeutic areas
  • Expanding pharmaceutical portfolio through strategic partnerships
Financial Vision Metrics
Financial Metric 2024 Projection
Revenue Forecast $320-$350 million
R&D Investment $85-$95 million
Market Capitalization Approximately $1.2 billion
Product Development Vision

Coherus targets development of:

  • Oncology biosimilars
  • Innovative immunology therapeutics
  • Next-generation biopharmaceutical treatments
Market Expansion Objectives
Geographic Region Expansion Strategy
United States Primary market focus
European Union Selective market entry
Asia-Pacific Partnership development



Core Values of Coherus BioSciences, Inc. (CHRS)

Core Values of Coherus BioSciences, Inc. (CHRS)

Innovation and Scientific Excellence

Coherus BioSciences demonstrates commitment to innovation through significant R&D investments.

R&D Metric 2024 Value
R&D Expenses $87.4 million
Patents Filed 12 new patents

Patient-Centric Approach

Commitment to patient care through targeted therapeutic developments.

  • Oncology treatment portfolio expansion
  • Biosimilar development targeting cost reduction
  • Patient access programs

Operational Integrity

Compliance Metric 2024 Performance
FDA Compliance Ratings 100% compliance
Regulatory Audit Findings Zero critical observations

Sustainability and Corporate Responsibility

Environmental and social governance metrics:

  • Carbon emission reduction: 22% year-over-year
  • Diversity in leadership: 45% women in executive positions
  • Community investment: $2.3 million in healthcare initiatives

DCF model

Coherus BioSciences, Inc. (CHRS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.